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Abstract
Background: Atrial thrombus formation in patients with atrial flutter raises concerns of
stroke risk. We investigated patients with isthmus-dependent atrial flutter for coagulation
abnormalities before and after cardioversion to sinus rhythm by catheter ablation, and evalu-
ated the relationship of the abnormalities to the echocardiographic risk markers of stroke.
Methods and results: Plasma samples were drawn prior to insertion of catheters, immedi-
ately after the procedure, and 24 hours afterwards. At baseline, coagulation abnormalities
were found in 22 out of 25 patients (88%). von Willebrand factor antigen (vWF-Ag) and factor
VIII:C were elevated in 17 patients (68%) and 15 patients (60%), respectively. At baseline,
mean plasma levels of vWF-Ag (250.1 ± 144.4%) and factor VIII:C (215.0 ± 77.1%) were
increased. Key markers of thrombin generation, thrombin-antithrombin III complex (TAT;
47.8 ± 30.9 µg/L vs 14.5 ± 13.8 µg/L; p < 0.05) and prothrombin fragments 1.2 (F1.2;
2.5 ± 0.5 nmoL/L vs 1.2 ± 1.0 nmoL/L) were significantly elevated in the presence of
spontaneous echo contrast. Further, both markers of thrombin generation inversely correlated
with left atrial appendage emptying velocity (r = –0.42 and –0.63, p < 0.05). Levels of TAT
and F1.2 increased after conversion and ablation.
Conclusions: Endothelial-dependent coagulation factors were enhanced in most patients
with atrial flutter. Spontaneous echo contrast and decreased atrial contractility were associated
with increased thrombin generation. After conversion and ablation, an increase in thrombin
generation and fibrinolysis suggest a transient pro-thrombotic state. (Cardiol J 2010; 17, 4: 390–396)
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Introduction
Reports of atrial thrombus on transesophageal
echocardiography and embolic events after cardio-
version of atrial flutter (AFL) suggest a greater risk
of stroke than previously thought [1–4]. After ter-
mination of AFL by direct current cardioversion or
radiofrequency (RF) ablation, patients have an in-
creased incidence of thromboembolism and frequent-
ly demonstrate spontaneous echo contrast and de-
creased left atrial appendage emptying velocity [3,
5–9]. In this study, we investigated the potential ab-
normalities of the coagulation system associated with
AFL before and after conversion by ablation. Further,
given the paucity of published data, we studied the
relationship of coagulation abnormalities to the
echocardiographic markers of thromboembolic risk.
Methods
Patient selection and study design
The study group consisted of 25 consecutive
patients with drug-refractory AFL undergoing RF
ablation. The 12-lead electrocardiogram showed
f-wave morphology consistent with typical counter-
clockwise or clockwise AFL. Isthmus-dependent
flutter was confirmed by right atrial mapping and
entrainment at sub-eustachian isthmus. After con-
firmation, RF ablation was performed in the stan-
dard fashion. Warfarin was held for > five days pri-
or to procedure in six patients; 19 patients had not
been anticoagulated. Aspirin was not held prior to
the procedure and none of the included patients
were on clopidogrel.
The control group included ten patients who
underwent ablation for other supraventricular ta-
chycardias. Excluded from this study were patients
with coexistent paroxysmal atrial fibrillation (AF),
anticoagulation with heparin or warfarin during the
five days preceding the ablation procedure, pros-
thetic heart valve, recent thrombotic or throm-
boembolic event (< four weeks), conditions likely
to affect hemostasis or activation of the clotting
system (e.g. recent surgery, infection, inflamma-
tion, malignancy, etc.), and patients unable or un-
willing to consent to transesophageal echocardio-
graphy. The study was approved by the local Insti-
tutional Review Board and all patients provided
signed informed consent.
Blood sampling and measurement
of coagulation parameters
Venous blood was drawn before catheter inser-
tion and immediately after the procedure in both
study groups, and another sample was drawn 24 hours
post-ablation in the AFL group. Blood was drawn
from the antecubital vein to avoiding clotting or ex-
travasation. Blood was mixed with sodium citrate
solution (ratio 9:1), and centrifuged at 1500 xg for
at least 10 min. Supernatant plasma was withdrawn
and stored in several aliquots at –80°C until assay,
and thawed at 37°C immediately prior to analysis.
As markers of endothelium dependent coagulation,
we measured von Willebrand factor antigen (vWF-
-Ag; normal range 54–163%) and factor VIII:C  (nor-
mal range 69–182%). As markers of thrombin gen-
eration, we measured prothrombin fragments 1.2
(F1.2; normal range 0.4–1.1 nmoL/L) and thrombin-
antithrombin III complex (TAT III; normal range
1.0–4.1 µg/L). And to assess fibrinolytic activity, we
measured fibrinogen (normal range 200–400 mg/dL)
and D-dimer levels (normal range < 0.44 µg/mL).
All assays were performed in batches accor-
ding to reagent manufacturer recommendations.
vWF-Ag activity was measured by enzyme-linked
immunoabsorbent assay (ELISA). Activity of factor
VIII:C was assessed by a standard one-stage clot-
ting time. The fibrinogen activity was determined
by the Clauss clotting technique and D-dimer le-
vels by an immunoturbidimetric method. All of the
above measurements were performed using re-
agents and instrumentation (Diagnostica Stago,
Asnieres-sur-Seine, France). F1.2 and TAT were
measured by ELISA using commercially available
kits (Behringwerke, Marburg, Germany). All mi-
crotitreplate measurements were performed with
a Dynatech MR4000 (Dynex Laboratories, Chan-
tilly, VA, USA).
Echocardiographic studies and analysis
All patients underwent transthoracic and
transesophageal echocardiography (TEE) before
the invasive procedure. Measured TEE parameters
included left ventricular ejection fraction (LVEF)
and dimensions, left atrial diameter, left atrial ap-
pendage (LAA)  function, and presence of throm-
bus and/or spontaneous echo contrast (SEC; defined
as dynamic smoke-like echocardiographic images
with a swirling motion that persisted after decreas-
ing the gain). Left atrial appendage emptying ve-
locity (LAA-EV) was assessed by pulsed wave Dop-
pler placing the sample volume 1.5 cm into the
mouth of the atrial appendage in the basal trans-
verse plane at the level of the aortic valve. Peak flow
velocities at end-diastole were measured and ave-
raged over six cardiac cycles. Measured transtho-
racic echo parameters included right and left atrial
dimensions (right atrial enlargement was defined
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as right atrial area > 20 cm2 in the four chamber
view, left atrial diameters were measured in the
para-sternal long axis view), LVEF (Simpson’s
method), pulmonary arterial pressure and assess-
ment of valve function.
Statistical analysis
All continuous variables are expressed as
mean ± standard deviation. Categorical variables
are summarized as absolute number and relative
frequencies (%). Changes in the pre and post mea-
surements were compared using the non-paramet-
ric Wilcoxon matched-pairs signed ranks test. The
Mann Whitney test was used to compare the change
between the two groups. Analysis of variance for
repeated measures was used to analyze changes in
the pre-post and 24 hours measurements. Logistic
regression analysis was used to identify correlates
of elevation in coagulation parameters. SPSS ver-
sion 15.0 (SPSS Inc, Chicago, IL) was used for the




Clinical data and echocardiographic findings
(n = 25) are displayed in Tables 1 and 2. All 25 pa-
tients were successfully ablated.
Coagulation abnormalities
Abnormalities among the parameters tested
were found in 22 of the 25 patients (88%). Both
vWF-Ag and factor VIII:C were frequently elevat-
ed [17 patients (68%) and 15 patients (60%), respec-
tively] and mean plasma levels of vWF-Ag and fac-
tor VIII:C were increased (Fig. 1A) above normal
values. Also, elevated levels of F1.2, TAT and fibri-
nogen were frequently encountered (Figs. 1B, C).
Multivariate analyses using baseline clinical
parameters (age, gender, hypertension, coronary
artery disease) identified the presence of coronary
artery disease (HR = 33.5, CI 1.5–757.8, p = 0.03)
to be correlated with higher fibrinogen levels. No
other clinical parameters were correlated with other
coagulation abnormalities.
Evolution of coagulation abnormalities
after conversion and ablation
Both F1.2 (p = 0.003) and TAT levels (p = 0.03)
were increased immediately following conversion
and ablation, with a decrease 24 hours after the pro-
cedure (Fig. 2). No significant changes in levels of
vWF-Ag were noted after conversion and ablation.
There was a trend for D-dimer levels (p = 0.08) and
factor VIII:C levels (p = 0.08) to be elevated after
ablation compared to pre-ablation values and remain
elevated 24 hours after ablation.
Relationship of coagulation abnormalities
to echocardiographic parameters
At baseline, SEC was demonstrated in four of
the 25 patients (16%) with AFL. Patients with SEC
had significantly elevated markers of thrombin gen-
eration, F1.2 and TAT levels, when compared to
patients without SEC (p < 0.05, Table 3). Plasma
levels of F1.2 (r = –0.63, p < 0.01) and TAT (r =
= –0.42, p < 0.05) were inversely related to LAA-EV
(Fig. 3, Table 4). Coagulation parameters did not
Table 1. Clinical characteristics (n = 25).
Age (years) 60 ± 8
Male 17 (68%)
Median duration of AFL (days) 222
Rate of AFL (beats/min) 255 ± 27
Ventricular rate in AFL (beats/min) 85 ± 18
Cardiovascular disease: 17 (68%)
Hypertension 17 (68%)
Diabetes mellitus 3 (12%)
Coronary artery disease 10 (40%)
Cardiomyopathy 7 (28%)
AFL — atrial flutter
Table 2. Echocardiographic findings (n = 25).
Left ventricular ejection fraction 40 ± 16%





Mild (PAS > 35 mm Hg) 7 (28%)
Moderate (PAS > 50 mm Hg) 1 (4%)





Right atrial enlargement 21 (84%)
Left atrial diameter [mm] 5.2 ± 0.3
Left atrial appendage 43 ± 19
emptying velocity [cm/s]
Left atrial appendage 10 (40%)
emptying velocity £ 30 cm/s
Spontaneous echo contrast 4 (16%)
PAS — pulmonary artery systolic pressure
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differ in patients with or without left ventricular dys-
function (Table 5).
Control group
At baseline, all coagulation parameters were
within normal range, except a mild elevation in the
TAT (7.4 ± 6.7 µg/L) was noted. Immediately post-
ablation, there was a significant increase in the ele-
vated markers of thrombin generation, F1.2 and
TAT levels, but these values still remained well
below baseline values in the AFL group (Table 6).
Discussion
This study demonstrates activation of the co-
agulation system in patients with isthmus-depen-
dent AFL. Patients with echocardiographic evi-
dence of spontaneous echo contrast and decreased
LAA-EV had elevated levels of thrombin genera-
tion. Evidence of increased thrombin generation
(elevated F1.2 and TAT) and intravascular fibrin
turnover (decreased fibrinogen and increased
D-dimer levels) after conversion and ablation raise
the possibility of a transient pro-thrombotic state
following ablation and/or termination of AFL. Pa-
tients with supraventricular tachycardia did not
show evidence of coagulation system activation at
baseline and had lesser activation following the ab-
lation procedure.
Implications of endothelial-dependent
activation of the coagulation system
In most patients, vWF-Ag and factor VIII:C
levels were elevated at baseline. These results ac-
cord with data reported in patients with non-valvu-
lar AF [10, 11]. Plasma levels of vWF-Ag and fac-
tor VIII:C did not correlate with LAA-EV, LVEF or
the presence or absence of SEC. vWF-Ag is impor-
tant in mediating platelet adhesion and is a marker
for endothelial dysfunction. Immunohistochemistry
studies of vWF-Ag in endothelial cells harvested
from the LAA of patients with and without AF un-
dergoing heart surgery, or at autopsy in normal
controls, revealed an increase of immunoreactive
vWF-Ag in the endocardium of the pressure over-
loaded atrial appendage (particularly with mitral
valve disease), irrespective of AF [12]. The finding
that elevated plasma levels of vWF-Ag and factor
VIII:C in most of our patients with AFL may reflect
a coagulation abnormality at the endocardial level
which is independent of stasis or poor atrial con-
tractile function. In this study, coronary artery dis-
ease was associated with higher fibrinogen levels.
These results are similar to previous studies that
demonstrated markers of inflammation (fibrinogen,
C-reactive protein and serum amyloid) are positive-
ly associated with prevailing coronary artery dis-
ease [13].
Evidence of increased thrombin generation
and fibrinolytic activity after isthmus ablation
Markers of thrombin generation (F1.2 and
TAT) levels increased one hour after conversion
and ablation and remained elevated above pre-abla-
tion levels even 24 hours after ablation (Fig. 3).
Figure 1. Baseline coagulation parameters: A. Endothe-
lium dependent coagulation — factor VIII:C (left) and
von Willebrand factor antigen — vWF-Ag (right);
B. Thrombin generation: F1.2 (left) and TAT (right);
C. Fibrinolytic activity: Fibrinogen (left) and D-dimer (ri-
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D-dimer levels increased after isthmus ablation, and
fibrinogen levels tended to decrease consistent with
increased fibrin formation and fibrinolytic activity
following flutter ablation and/or termination. Our
study is consistent with recent data suggesting that
ablation of AFL induces a prothrombotic state as
evidenced by elevation of procoagulant microparti-
cles [14]. Similarly to our study, vWF and D-dimer
levels remained elevated post-ablation reflecting an
ongoing prothrombotic state [14]. Enhanced throm-
bin generation and intravascular fibrin turnover af-
ter ablation could be due to activation of coagula-
tion system during venous sheath and catheter
placement, endocardial injury after delivery of RF
Table 3. Relationship of presence of spontaneous
echo contrast (SEC) and coagulation system activity.
SEC No SEC P
(n = 4)  (n = 21)
vWF-Ag (%) 243±86 210±76 NS
Factor VIII:C (%) 269±38 247±157 NS
F1.2 [nmol/L] 2.5±0.5 1.2±1.0 < 0.05
TAT [mg/L] 47.8±30.9 14.5±13.8 < 0.01
Fibrinogen 490±95 401±129 NS
[mg/dL]
D-dimer [mg/mL] 1.3±0.9 1.5±3.6 NS
vWF-Ag — von Willebrand factor antigen; TAT — thrombin-anti-
thrombin III complex; F1.2 — prothrombin fragments 1.2
Figure 2. Coagulation parameters before and after conversion and ablation. An increased level of F1.2 and TAT
immediately after ablation (bottom row) is consistent with enhanced thrombin generation during the first hours
following ablation. The trend towards elevated D-dimer levels (middle row) persisting beyond the first 24 hours after
ablation suggests increased fibrinolytic activity; Abl — ablation.
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Table 4. Relationship of left atrial appendage
emptying velocity (LAA-EV) and coagulation
system activity.
LAA-EV LAA-EV P
£ 30 cm/s > 30 cm/s
(n = 10) (n = 15)
vWF-Ag (%) 232±80 204±76 NS
Factor VIII:C (%) 250±76 252±179 NS
F1.2 [nmol/L] 2.1±1.2 1.0±0.9 < 0.05
TAT [mg/L] 33.5±26.6 10.7± 8.2 < 0.05
Fibrinogen 470±89 379±138 0.08
[mg/dL]
D-dimer [mg/mL] 2.52±5.06  0.70±0.98 NS
vWF-Ag — von Willebrand factor antigen; TAT — thrombin-antithrom-
bin III complex; F1.2 — prothrombin fragments 1.2
Figure 3. Correlation of left atrial appendage (LAA) emptying velocity with markers of thrombin generation. Plasma
levels of F1.2 (A) and TAT III (B) were inversely related to left atrial appendage velocity.
Table 5. Relationship of left ventricular ejection
fraction (LVEF) and coagulation system activity.
LVEF LVEF P
£ 35% > 35%
(n = 11)  (n = 14)
vWF-Ag (%) 219±91 212±68 NS
Factor VIII:C (%) 298±184 214±95 NS
F1.2 [nmol/L] 1.7±1.4 1.2±0.9 NS
TAT [mg/L] 22.7±24.9 17.6±17.6 NS
Fibrinogen
[mg/dL] 427±107 406±144 NS
D-dimer [mg/mL] 2.37±4.92 0.69±0.58 NS
vWF-Ag — von Willebrand factor antigen; TAT — thrombin-antithrom-
bin III complex; F1.2 — prothrombin fragments 1.2
energy, and/or atrial stunning after termination of
AFL [14, 15]. This continuation of prothrombotic
and increased fibrinolytic state post-ablation would
necessitate continuation of anticoagulation follow-
ing ablation of AFL.
Enhanced thrombin generation
and impaired atrial contractility
Previous studies have demonstrated eleva-
ted plasma levels of fibrinogen and D-dimer in pa-
tients with chronic AF [10, 11, 13, 16]. In patients
with AF, Black et al. [1] have reported that SEC was
associated with increased plasma fibrinogen, sug-
gesting a hypercoagulable state in addition to stasis.
Table 6. Baseline and post-ablation coagulation
parameters in the control group.
Pre- Post- P
ablation ablation
(n = 10) (n = 10)
vWF-Ag (%) 86.2±28.2 98.0±37.6 NS
Factor VIII:C (%) 88.6±62.2 82.1±28.3 NS
F1.2 [nmol/L] 0.9±0.6 1.4±0.6 0.05
TAT [mg/L] 7.4±6.7 15.6±22.1 NS
Fibrinogen 328.0±72.8 344.5±53.2 NS
[mg/dL]
D-dimer [mg/mL] 0.4±0.2 1.8±1.1 0.02
vWF-Ag — von Willebrand factor antigen; TAT — thrombin-antithrom-
bin III complex; F1.2 — prothrombin fragments 1.2
A B
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This study revealed elevated plasma levels of TAT
in patients with AFL. Similar studies in patients
with AF have demonstrated that 1) TAT is eleva-
ted compared to age-matched control subjects [13],
and 2) TAT tends to be higher in patients with AF
> 12 hours duration compared to < 12 hours in
duration [16]. In patients with AFL, Sakurai et al.  [17]
reported that impaired LAA function and SEC was
associated with elevated D-dimer and beta-throm-
boglobulin levels, suggesting a potentially higher
risk for thromboembolism. This study confirmed
these findings and further demonstrated that pre-
sence of SEC is associated with elevated levels of
F1.2 and TAT, which also showed a moderate in-
verse correlation to LAA-EV. In addition, plasma
fibrinogen levels tended to be higher in AFL pa-
tients with decreased LAA-EV.
Limitations of the study
It is possible that our findings might be in part
secondary to cardiovascular disease or to the inter-
ruption of anticoagulation, although like AF, AFL
is well documented to generate a thrombogenic
state. However, normal baseline values of nearly
all coagulation parameters in the control group sug-
gest that activation of coagulation system may in-
deed be related to AFL.
Conclusions
Patients with isthmus-dependent AFL demon-
strated endothelial-dependent activation of the co-
agulation system and enhanced thrombin genera-
tion in the setting of decreased atrial contractility
and SEC. A greater increase in thrombin and fibri-
nolytic activity was found after AFL termination by
ablation. It remains to be determined how valuable
these coagulation factors are as predictors of em-
bolic events and stroke in patients with AFL.
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